-0.61%
3.16%
-6.86%
-22.01%
35.83%
-74.57%
41.74%
AI Spotlight on INCR
Company Description
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally.It offers dried cannabis inflorescences and cannabis extract mixed with oil.The company also invests in biomed sector.
InterCure Ltd.was incorporated in 1994 and is headquartered in Herzliya, Israel.
Market Data
| Last Price | 1.63 |
| Change Percentage | -0.61% |
| Open | 1.6 |
| Previous Close | 1.64 |
| Market Cap ( Millions) | 75 |
| Volume | 5679 |
| Year High | 3.72 |
| Year Low | 1.17 |
| M A 50 | 1.54 |
| M A 200 | 2.06 |
Financial Ratios
| FCF Yield | 0.00% |
| Dividend Yield | 0.00% |
| ROE | -14.34% |
| Debt / Equity | 32.75% |
| Net Debt / EBIDTA | 2598.40% |
| Price To Book | 0.61 |
| Price Earnings Ratio | -4.26 |
| Price To FCF | 0 |
| Price To sales | 0.98 |
| EV / EBITDA | 79.12 |
News
- Dec -20 - InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
- Sep -14 - Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
- Aug -29 - InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
- Aug -28 - InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
- Jun -30 - InterCure: A Cannabis Industry Leader Still Flying Under The Radar
- May -22 - InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference
- May -01 - InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
- Apr -22 - InterCure: Bargain Israel Cannabis Play
- Mar -22 - InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
- Feb -23 - PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape
- Feb -13 - InterCure Provides an Update Regarding Nir Oz Facility
- Jan -31 - InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
- Oct -31 - InterCure Wins Cannolam Arbitration Proceeding
- Oct -17 - InterCure Provides an Update Regarding the Security Situation in Israel
- Aug -31 - InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY
- Aug -02 - InterCure: Leader In Israel's Growing Medical Cannabis Market
- Jul -10 - InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
- Apr -04 - InterCure Ltd. (INCR) Q4 2022 Earnings Call Transcript
- Apr -03 - InterCure Reschedules 2022 Full Year Results Conference Call
- Jan -20 - InterCure: Why The Company Is Grossly Undervalued By Wall Street
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Cannabis
Expected Growth : 20.5 %
What the company do ?
Cannabis from InterCure Ltd. is a high-quality, pharmaceutical-grade cannabis product for medical and recreational use, cultivated and manufactured in Israel.
Why we expect these perspectives ?
Growing demand for medical and recreational cannabis, increasing legalization, and InterCure's high-quality pharmaceutical-grade products position the company for significant growth in the global cannabis market.
Intercure Ltd. Products
| Product Range | What is it ? |
|---|---|
| Cannabis Flos | High-quality cannabis flowers for medical and recreational use |
| Cannabis Oil | Concentrated cannabis oil for medical and recreational use |
| Vapes | Portable and discreet cannabis vaporizers for on-the-go use |
| Edibles | Cannabis-infused food and beverages for recreational and medical use |
| Topicals | Cannabis-infused creams, balms, and salves for localized relief |
| Pharmaceuticals | Cannabis-based pharmaceuticals for medical treatment |
InterCure Ltd.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for InterCure Ltd. is medium due to the availability of alternative products in the market.
Bargaining Power Of Customers
The bargaining power of customers for InterCure Ltd. is high due to the concentration of buyers in the market.
Bargaining Power Of Suppliers
The bargaining power of suppliers for InterCure Ltd. is low due to the availability of multiple suppliers in the market.
Threat Of New Entrants
The threat of new entrants for InterCure Ltd. is medium due to the moderate barriers to entry in the market.
Intensity Of Rivalry
The intensity of rivalry for InterCure Ltd. is high due to the high level of competition in the market.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 30.07% |
| Debt Cost | 5.15% |
| Equity Weight | 69.93% |
| Equity Cost | 5.15% |
| WACC | 5.15% |
| Leverage | 43.00% |
InterCure Ltd. : Quality Control
InterCure Ltd. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PSG.DE | PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream … |
| PHN.MI | Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The … |
| PPGN.SW | PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, … |
| PROB.ST | Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune … |
| BMK.L | Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that supports the development of food and farming industries in the United Kingdom, Norway, the Faroe … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
PharmaSGP Holding
A-Score
1-Year Total Return ->
🥈
Pharmanutra
A-Score
1-Year Total Return ->
🥉
PolyPeptide
A-Score
1-Year Total Return ->
4
Benchmark
A-Score
1-Year Total Return ->
5
Probi
A-Score
1-Year Total Return ->
6
